Makoto Watanabe, MD; Naruaki Kohge, MD; Takekazu Kaji, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Watanabe M., Kohge N., Kaji T.; Severe Hepatitis in a Patient Taking Cetirizine. Ann Intern Med. 2001;135:142-143. doi: 10.7326/0003-4819-135-2-200107170-00020
Download citation file:
Published: Ann Intern Med. 2001;135(2):142-143.
TO THE EDITOR:
A 23-year-old man with jaundice and general malaise was admitted to our hospital on 24 April 2000. He was not an alcoholic or an intravenous drug user. He had been taking cetirizine, 10 mg/d, since July 1999 for atopic dermatitis; he was taking no other drugs. Physical examination revealed jaundice without ascites or encephalopathy. Laboratory tests showed a serum total bilirubin level of 99 µmol/L (5.8 mg/dL), a direct bilirubin level of 3.4 mg/dL, an aspartate aminotransferase level of 28.80 µkat/L (1728 IU/L), an alanine aminotransferase level of 41 250 nkat/L (2475 IU/L), moderately elevated biliary enzyme levels, a prothrombin time of 17.6 seconds, and a value of 25% on a hepaplastin test. Blood counts were all within normal ranges, except for the eosinophil count (13%). Results of tests for known hepatitis virus markers and autoantibodies were all negative. Because the patient was in serious condition, prednisolone was administered (60 mg/d in three divided doses for the first 3 days followed by 40 mg/d for 3 days and 30 mg/d for an additional 3 days).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only